IRCT20210614051574N5已完成2 期
Effect of Thalidomide on moderate COVID-19 pneumonia
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 75 years（—）
- 性别
- All
入选标准
- •Definitive laboratory results for Covid-19
- •Radiographic results of lung injury and infection
- •Less than 5 days have passed since the confirmation of the infection
- •Moderate disease severity based on the World Health Organization classification criteria
排除标准
- •Breastfeeding
- •Receive thalidomide or other experimental drugs related to the treatment of Covid-19 within one month prior to enrollment
- •Existence of a history of thromboembolism unrelated to recent Covid-19 disease
- •History of interstitial lung disease
研究者
相似试验
撤回
4 期
The Use of Tadalafil in Confirmed COVID-19 Pneumonia.COVIDSars-CoV2ARDS, HumanNCT04946162Santa Barbara Cottage Hospital
进行中（未招募）
1 期
Adalimumab for Coronavirus in Community CareEUCTR2020-003628-18-GBniversity of Oxford, Clinical Trials and Research Governance750
招募中
2 期
se of thalidomide in complicated tubercular infection of braiCTRI/2023/05/052417PGIMER Chandigarh
已完成
3 期
Effect of Thalidomide in Covid 19 pneumoniaPneumonia caused by Coronavirus 2019, COVID19.Coronavirus infection, unspecifiedB34.2IRCT20200428047232N1Esfahan University of Medical Sciences60
终止
3 期
Efficacy of Amantadine Treatment in COVID-19 PatientsPatients With Moderate or Severe COVID-19NCT04952519Noblewell193